Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

Michelle L O'DonoghueRobert S RosensonBaris GencerJ Antonio G LópezNorman E LeporSeth J BaumElmer StoutDaniel GaudetBeat KnuselJulia F KuderXinhui RanSabina A MurphyHuei WangYou WuHelina KassahunMarc S Sabatinenull null

Published in: The New England journal of medicine (2022)

Olpasiran therapy significantly reduced lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease. Longer and larger trials will be necessary to determine the effect of olpasiran therapy on cardiovascular disease. (Funded by Amgen; OCEAN[a]-DOSE ClinicalTrials.gov number, NCT04270760.).

Keyphrases

cardiovascular disease
type diabetes
cardiovascular risk factors
metabolic syndrome
low density lipoprotein
mesenchymal stem cells
cell therapy